This Web site is best viewed with Firefox, Chrome, or Safari browsers.

Speaker Profile


G. Steven Burrill
Chief Executive Officer
Burrill & Company
One Embarcadero Center, Suite 2700
San Francisco, CA 94111
- University of Wisconsin, BBA

Speech Topic : Keynote Address
“A Global Look at the Life Sciences Industry: Opportunities and Challenges”

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. Mr. Burrill founded and has been Chief Executive Officer of Burrill & Company, a venture capital and merchant banking firm, since 1994. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the field of biotechnology, life sciences, high technology, and manufacturing worldwide. He currently serves on the Boards of Directors of AliveCor (Chairman), Catalyst Biosciences, Depomed (NASDAQ: DEPO), NewBridge, Novadaq (NASDAQ: NVDQ), and XDx. Previously he served as Chairman of the Boards of BioImagene, Abunda Nutrition and Pharmasset.
Mr. Burrill is a founder and currently serves as Chairman of the Board of the National Science and Technology Medals Foundation (NSTMF). He chaired the National Research Council study on linkages in biotechnology between Japan and the United States and was also involved with the US-Japan Science and Technology Agreement Study of Technology Transfer Mechanisms between the US and Japan. His other non-profit activities include serving as Chairman of the Boards of Directors of the Life Science Foundation, the World Council for Ethical Standards, the Vilas County (Wisconsin) Economic Development Corporation (VCEDC) and as Vice Chairman of the National Health Museum. He also serves on the Boards of the Bay Area Science Infrastructure Consortium, BayBio (Emeritus), The Buck Institute for Research on Aging, California Healthcare Institute (Emeritus), The Exploratorium (Emeritus), Gladstone Foundation, Global Virus Network (GVN), Kellogg Center for Biotechnology, MIT Center for Biomedical Innovation, BIO Ventures for Global Health (BVGH), Harvard Medical School Genetics Advisory Council and NIH Scientific Management Review Board.
In 2012 Mr. Burrill received the Richard Bolte, Sr. Award for Supporting Industries from the Chemical Heritage Foundation in Philadelphia for his biotechnology industry leadership worldwide. In 2011 he received a lifetime achievement award at Scrip Intelligence’s annual Scrip Award ceremony in London. That same year he received the Breath of Life Award from the Northern California Chapter of the Cystic Fibrosis Foundation to honor his contributions to the life sciences industry. In 2008 he received both the BayBio Pantheon DiNA lifetime achievement award for his biotech leadership worldwide, and the Alan Cranston Living Legend Award for his central role in advancing biomedical research globally. In 2002 he was recognized as a biotech investment visionary by the Scientific American magazine (The Scientific American 50), and was also honored that year at the American Liver Foundation’s Annual “Salute to Excellence” Gala, which honors the leaders from the Bay Area’s medical, biotech and bio-pharmaceutical industries. In 1995 Mr. Burrill received BIO’s “service award” for his global biotechnology leadership.
He serves on the editorial boards of Scientific American, the Journal of Commercial Biotechnology and Life Science Leader and on the advisory boards of the Center for Policy on Emerging Technologies (C-PET) and BioAg Gateway, City of Madison. He is an advisor to the University of Illinois Institute for Genomic Biology, the University of Wisconsin-College of Agriculture and Life Sciences, the University of Minnesota College of Biological Sciences, University of California, Davis, and Duke University, and is an adjunct professor at University of California, San Francisco. He also serves on the Advisory Boards for the Department of Biology at San Francisco State University and the Biotechnology Master’s Program in the Department of Biology at the University of San Francisco. He serves on the BioNJ Diagnostics and Personalized Medicine Committee.
Mr. Burrill earned a BBA degree from the University of Wisconsin, Madison.



Shirley Vincent Ramesh
Former Senior Officer
in the Trade and Facilitation Division of the ASEAN Secretariat

Speech Topic : Track 1 - ASEAN Harmonization on Pharmaceuticals:- AEC and Beyond

Shirley Vincent Ramesh, a former Senior Officer in the Trade and Facilitation Division of the ASEAN Secretariat overseeing the standards and conformance activities in ASEAN, is a Regional Trade Specialist on Policies and Regulatory Affairs for Product Safety in ASEAN.
She is a Chemist by training with laboratory experience in manufacturing facilities to carry out the quality control and quality assurance functions as well as product formulation and research and development.
Having had in-depth experience in the field of standardization at national, regional and international levels, she provides support to the ASEAN Member States on the regional activities related to formulation of policies and implementation of strategies to address Technical Barriers to Trade (TBTs) under the economic integration initiatives of ASEAN. She was instrumental in the implementation of the ASEAN Economic Community Blueprint measures for standards and conformance, which includes formulation of policies and recommendations on the harmonisation of standards, technical regulations and conformity assessment procedures for a diverse range of sectors namely, agro-based products, automotive products, building and construction materials, cosmetics, electrical and electronic equipment, health supplements, medical devices, pharmaceuticals, rubber-based products, traditional medicines and wood-based products.
She was also actively involved in the Free Trade Area (FTA) negotiations on provisions for TBTs and Sanitary and Phyto-Sanitary (SPS) Measures by providing support to the ASEAN Member States on the facilitation of FTAs negotiations and its implementation with Dialogue Partners as well as the development and implementation of technical assistance programmes.


Christina Lim nee Tong
Senior Director
Health Sciences Authority Academy
- University of Singapore (Chalmers medalist), Bachelor of Pharmacy degree
- University of Montpellier, Ph.D. (Honors List) in Pharmacodynamics

Speech Topic : Track 1 - ASEAN Harmonization on Pharmaceuticals:- AEC and Beyond

Christina joined the Health Sciences Authority of Singapore in Jan 2007.  She is currently Senior Director of the HSA Academy, and was the immediate past Group Director of the Health Products Regulation Group (HPRG) of HSA, being responsible for the Group’s activities in regulating health products, including medicines, medical devices, complementary health products and cosmetics.
She has a Bachelor of Pharmacy degree from the University of Singapore (Chalmers medalist), and has a Ph.D. (Honors List) in Pharmacodynamics from the University of Montpellier in France.  She is fluent in both English and French, and conversant in Mandarin.

Theingi Zin
Deputy Director
Food and Drug Administration
No.47, Naypyitaw
- University of Medicine in Yangon, M. Med. Sc. In Pharmacology
- University of Medicine in Yangon, M.B.
- University of Medicine in Yangon, B.S.

Speech Topic : Track 1 - ASEAN Harmonization on Pharmaceuticals:- AEC and Beyond

I started to work at National Health Laboratories, Department of Health since 1992 and then transfer to Food and Drug Administration in 1995. I worked in pharmacology Laboratory and then transfer to Drug Control section, Food and Drug Administration.I attended in WHO and International  training and workshop, seminar, meeting. I also studied short term training programme in Japan, Korea. My present duty are overall drug control activity both premarket as well as post market surveillance.


Charlotte Enghave Fruergaard, Ph.D.
- Director of Nordic Competences
- The Chairman of ISPE
NNE Pharmaplan
Nybrovej 80
2820 Gentofte
- Copenhagen University College of Engineering, EBA in 
  Enginnering Business Administration
- Danmarks Tekniske Universitet, Ph.D. in Mechanical Engineering

Speech Topic : Track 2 & 2A - Role of ISPE in the region & Sterile technology

Charlotte Enghave Fruergaard, PhD, is employed as Director, Nordic Competences at NNE Pharmaplan.
Previously she was manager of Sales & Marketing and before that responsible for conceptual designs of new pharmaceutical facilities. Enghave Fruergaard has over 18 years of experience with pharmaceutical projects. She has a broad experience within pharmaceutical manufacturing of sterile products and is a leading expert within isolator and barrier technology and associated sterilisation techniques. Enghave Fruergaard holds an MSc in mechanical engineering and a PhD in measuring technique. She has international experience from an EU founded project where she was stationed at Physicalische Technische Bundesanstalt in Germany. During this project, she also gained the PhD degree within metrology.
Enghave Fruergaard has been a Member of ISPE since 1995, and is the Chairman of the International Board of Directors. She is co-founder of ISPE Nordic Affiliate in 2000, and was Chairman of the Nordic Affiliate in 2006-2007. She is a member of ISPE Sterile Products Processing Community of Practice steering committee as well as on the Editorial Board for the magazine Pharmaceutical Engineering. Furthermore she has been the co-chairman of the yearly reoccurring ISPE “Barrier Isolation Technology Conference” in Europe since 1999.
NNE Pharmaplan is the world’s leading engineering and consulting company in the complex field of pharma and biotech. We cover all segments from biopharmaceuticals and vaccines to medical devices and help our customers develop, establish and improve their product manufacturing. NNE Pharmaplan employs 1,700 people at more than 30 locations around the world.
Engineering for a healthier world – our role in an industry that improves people’s lives worldwide. To learn more about our company, please visit


Deborah R Cohen
Senior Scientist
GE Healthcare Life Sciences     
- The State University of NJ, BA  in Biochemistry, Rutgers

Speech Topic : Track 2A - Future Manufacturing Plant for Production and Engineering/ Design of potent facility

1996 to present: Senior Scientist, GE Healthcare Life Sciences
1996 Manufacturing Scientist, Roche Molecular Systems
1995-1996 Associate Scientist, Merck & Co
1994-1995 QC Analyst, Celgene
1991-1993 Senior Associate Scientist, Celgene

Nihir Parikh
Business Development, Enterprise Solutions, Asia
GE Healthcare Life Sciences     
- Stanford University, MS in Chemical Engineering (focus:  
- UDCT (Mumbai), BE in Chemical Engineering

Speech Topic : Track 2A - Future Manufacturing Plant for Production and Engineering/ Design of potent facility

Currently, Business Development Manager, Asia, GEHC Life Sciences, Singapore
Previously, BioProcess Manager, Asia, GEHC Life Sciences, Singapore
Previously, Process Development Engineer, Genentech Inc., South San Francisco
Expertise and relevant Experience
• Manager business development in Asia, including commercial projects, engineering, coordination of government affairs, finance, regulatory and other contacts in support of opportunities
• Consultative interaction in over 20 bio manufacturing company projects with regard to facility flexibility, biologics downstream processes, scale up and chromatography equipment
• Hand on process scale up & technology transfer experience from lab scale to pilot plant to manufacturing for multiple Monoclonal Antibodies
• Developed multiple scenario based financial models and business plans
• Led various strategic marketing projects focused on Asia

Gaston Loo
IPT Pharm West Maintenance Lead
MSD International GmbH (Singapore Branch)
50 Tuas West Drive 638408

Speech Topic : Track 2B - Critical Utility Design and Maintenance

Gaston Loo joined MSD (legacy Schering-Plough Ltd) in 1999 and currently is the Maintenance Lead for Pharm West facility. He is responsible for all Engineering and Maintenance activities for the facility and actively involved in all Projects development such as participation in the engineering design, construction, commissioning, validation and start-up of Biotech sterile facility in 2001-2003.
His other responsibilities include operation and maintenance of the critical utilities system such as WFI & PFW and process engineering in the facility. Gaston has extensive knowledge on electrical, instrument calibration & maintenance, computer system validation, DCS / PLC / SCADA system installation and clean room / HVAC maintenance. Prior to MSD, he had more than 5 years engineering experiences in building automation industry, which include HVAC design / commissioning in SEA.
With extensive and diversified experiences in the plant maintenance, operation, design and project management, Gaston has acquired the synergistic knowledge and skills for establishing good engineering design feature in equipment and process system, selection of equipment and maintainability of equipment at design stage. He is also involved in the design, operation and maintenance of various validated monitoring system in the plant such as Environmental Monitoring System (EMS) and Utility Monitoring System (UMS).


Tantra Tantraporn
Partner in the Management Consulting Practice
Grant Thornton Management Consulting Co., Ltd.
18th Floor Capital Tower
All Seasons Place
87/1 Wireless Road
Lumpini Pathumwan
Bangkok 10330
- Rensselaer Polytechnic Institute, Master of Science in
  Management/ Information Systems
- University of South Australia, Master of Science in Advanced
  Business Practice

Speech Topic : Track 2B - Key Aspects of Comprehensive CMMS Implementation 

Tantra Tantraporn moved permanently to Thailand in early 1994 and is currently a Partner in the Management Consulting Practice.  Prior to joining Grant Thornton, Tantra held senior roles in multinational firms that included: Associate Director at PricewaterhouseCoopers, regional Senior Solution Architect at Hewlett Packard, Vice President Process Improvement at Hutchison CAT and Asia Pacific Business Consulting Director for Oracle Systems.
Tantra is a subject matter expert in operations management, with an emphasis in process analysis and reengineering.  He has 37 years of experience in power plant operations, engineering management, business requirement assessment, systems suitability and productivity improvement.  His background in engineering, IT and corporate management brings a realistic perspective to consulting engagements in:
•           Telecommunications
•           Information systems
•           Facilities management
•           Supply chain management
•           Utilities
•           Manufacturing
•           Banking
•           Operations management
•           Process reengineering
Sector experience
Financial services, telecommunications, IT, utilities, facilities management, non-profit organizations, manufacturing and government.
•           Certified Nuclear Power Plant Operator – U.S. Naval Nuclear Power Program
•           Submarine Systems Qualified – U.S. Navy
•           Bachelor of Science – Nuclear Engineering Technology from the University of the State of New
•           Master of Science – Management / Information Systems from Rensselaer Polytechnic Institute
•           Master of Science – Advanced Business Practice from the University of South Australia



Alain Kupferman
Industry Pharmacist

Speech Topic : Track 2C - Factory Design 

We are very honoured to have Mr. Alain Kupferman as one of our speakers; Mr. Alain Kupferman has a long experience in pharmaceutical process planning and Risk Management.
Mr. Alain Kupferman is active in the pharmaceutical industry since 1967. With over 40 years of experience in production, feasibility and conceptual studies, Master planning, GMP aspects, Technological aspects and personnel training to many pharmaceutical organizations in Europe and Asia. He was also Lecturer at the University of Strasbourg in France from 2006 to 2011.


Michael Wang
Director, Solution Consulting, APAC
Accelrys KK Singapore Branch
80 Robinson Rd.
#02-00 068898
- National University of Singapore, MSc

Speech Topic : Track 2C - The role of Manufacturing IT - An Integrated Approach (LIMS) 

2012 – Present
Director, Solution Consulting, APAC, Accelrys
Lead pre-sales team in APAC for sales of informatics solutions from Accelrys. Provide business impact analysis to prospects and customers. Provide consulting service to customers in lab management, computer validation and system deployment for LIMS, LES, ELN, etc.
2004 - 2012
Manager, Technical Sales, APAC, ThermoFisher Scientific
Lead the pre-sales team in APAC for sales of LIMS and CDS solutions from ThermoFisher. He has worked on projects in ONO, CSL, AMO, Glenmark, Weeda, Wuxipharma, etc as project manager, validation consultant, services consultant, etc.
2001 - 2004
LIMS Project Manager, Pfizer Manufacturing, Singapore
Lead the LIMS project team to implement and validate the LIMS system in the QC lab for the API plant. The system has passed US FDA audit without any findings.
1998 - 2001
Lab Supervisor, Schering Plough, Singapore
Set up the new DCL lab and lead a team of 15 chemists for instrument qualification, method validation and product testing. The lab has passed many audits from US FDA, corporate QA and local HSA.

Prateep Juavijitjan
Project Director & Chief Customer Officer
Vantage Business Solutions (Thailand) Co.,Ltd.
11th, 12th Floor, Home Place Office Building
283/52 Sukhumvit 55 (Thonglor)
Klong Ton Nua, Wattana
Bangkok 10110
- Thummasat University, Master Degree of Business Administration
- Chulalongkorn University, Bachelor Degree of Electrical Engineer

Speech Topic : Track 2C - The role of Manufacturing IT - An Integrated Approach (ERP)

Career Summary
Over 18 years of ERP implementation, Project management and business process improvement experiences in various industries such as Auto parts, Chemical, Packaging, Electric equipment, Foods & Beverage, Pharmaceutical etc. 
Service Capabilities
§  ERP Project Management
§  Implementation Consulting in Trade and Logistics,Production & MRP,  Project
§  Training in Trade and Logistics, Production & MRP, Project
Project Implementation Record
§  Exedy Co.,Ltd
§  Siam Calsonic Co.,Ltd
§  Microchip Co.,Ltd
§  Useful Food Co.,Ltd.
§  Siam Ruammit Co.,Ltd
§  Thai Summit Autoparts Co.,Ltd
§  Ampas Industries Co.Ltd.
§  SVI Co.,Ltd.
Professional Certification
Microsoft Dynamics Implementation Certified
Microsoft® Business Solutions Certified Professional in Axapta – Trade & Logistic
Microsoft® Business Solutions Certified Professional in Axapta  – Production
Microsoft Dynamics AX (2.5,3.4,2009,2012)
Baan IV
Baan ERP


Bikash K Chatterjee
President & Chief Technology Officer
Pharmatech Associates Inc.
22320 Foothill Blvd. Suite 330 
Hayward CA 94541
- University of California, B.A. in Biochemistry
- University of California, B.S. in Chemical Engineering

Speech Topic : Track 2D - Quality by Design (QbD) and Process Analytical Technology (PAT)

Mr. Chatterjee has more than 30 years’ experience in the pharmaceutical, biosciences, medical device/diagnostic and nutraceutical/dietary supplement industries. He has held senior management positions in operating companies for more than a decade and has successfully brought multiple drug and product platforms through the FDA regulated development process to market. Throughout his career he has been responsible for product development including Quality by Design, technology and process transfer and technology, process validation and established global supply chain processes in over 40 different countries around the world and been responsible for the commercialization of over a dozen products.
Mr. Chatterjee sits on several scientific advisory boards for pharmaceutical and medical device companies. He is a standing member of the editorial advisory board for Pharmaceutical Manufacturing and Pharmaceutical Technology Magazines and writes a recurring column for several magazines on industry trends and challenges. He has published over 70 articles and editorials throughout his career in peer reviewed journals.
Mr. Chatterjee is a Certified Lead Assessor and a Lean Six Sigma Master Black Belt. He holds a BA in Biochemistry and a BS in Chemical Engineering from the University of California at San Diego.



Ivana Knezevic, MD, MSc, PhD
Scientist, Quality Safety and Standards Unit
World Health Organization
Immunization, Vaccines and Biologicals Department
Geneva, Switzerland
- University of Belgrade, PhD in Medicine (Virology)
- University of Belgrade, MSc in Medicine (Microbiology)
- University of Novi Sad, MSc in Medicine (Microbiology)

Speech Topic : Track 6A - Biosimilars: aspect from WHO 

Dr Knezevic has nineteen years of professional experience in standardization and regulation of biologicals. During the first seven years, the expertise in the production, quality control and overall evaluation of vaccines and biological therapeutics was developed at the national level. In 2000, Dr Knezevic joined WHO Biological Standardization Programme and since then her activities have been devoted to the standardization and evaluation of biologicals at the global level. This includes development and establishment of WHO International Standards as well as the assistance to the regulators, manufacturers and other users of these standards. Since 2006, she has been leading standardization of vaccines and some biological therapeutics. Dr Knezevic led development of WHO regulatory guidelines on various aspects of vaccine evaluation (ie, stability, non-clinical and clinical) as well as the recommendations for production, control and evaluation of selected vaccines, published in WHO Technical Report Series. In the area of biotherapeutics, she coordinated development of the WHO Guidelines on evaluation of similar biotherapeutic products (SBPs) and has initiated a series of workshops to facilitate implementation of guiding principles into regulatory and manufacturers' practice. Dr Knezevic is also the author of several publications that made broad audience aware of WHO initiative in the development, establishment and implementation of standards for vaccines and some other biological products.
Dr. Knezevic is Specialist in Medical Microbiology and Parasitology. She received her MD from the University of Novi Sad, her MSc in Medicine (Microbiology) and PhD in Medicine (Virology) from the University of Belgrade, Republic of Serbia.

Martin Eisenhawer, Ph.D.
Technical Officer Strengthening Quality and Health Systems
World Health Organisation
South-East Asia Regional Office
Immunization and Vaccine Development
Office of the WHO Representative to Thailand
Permanent Secretary
Building 3, 4th floor, Ministry of Public Health,
Tiwanon Road, 11000
- Federal Institute of Technology of Lausanne, Ph.D. in Sciences
- University of Toledo, Organometallic Chemistry Research
- University of Münster, Diplomchemiker (Equivalent MSc Chemistry)

Speech Topic : Track 6A - cGMP on biopharmaceuticals compared to chemical drugs

Dr. Eisenhawer has fourteen years of professional experience in regulation, manufacturing and quality control of pharmaceutical products, mainly in the field of biologics. Following his PhD in Biophysics from the Federal Institute of Technology of Lausanne (EPFL), Switzerland, he worked for 5 years in the pharmaceutical industry and obtained various positions including head of quality management and head of quality control. He then worked for the Swiss National Regulatory Authority (Swissmedic) for 8 years, where he was responsible for conducting Good Manufacturing Practices and Good Distribution Practices inspections and providing scientific advice to manufacturers of biological pharmaceutical products including vaccines, blood, blood products, biotech products. During this time as the Swissmedic expert for sterile products, he was involved in establishment of various guidelines, including his contribution as the main author for the PIC/S interpretation of Annex 1 for sterile medicinal products. Dr. Eisenhawer has been involved in numerous WHO prequalification activities in South East Asia and also assessments of National Regulatory Authorities by PIC/S.  He served as a temporary advisor to WHO in various roles, including contributions to harmonization of EU and WHO GMP.  Dr. Eisenhawer joined the WHO South East Asia Regional Office in 2012 where he is responsible for capacity building of National Regulatory Authorities in the South East Asia Region in the context of regulations of vaccines.


Professor W. John Kao, Ph.D.
Professor of Pharmacy, Surgery, and Biomedical Engineering
University of Wisconsin-Madison
777 Highland Avenue, Madison,
WI 53705-2222
- Case Western Reserve University, Ph.D. in Macromolecular Sciences
- Case Western Reserve University, M.S.E. in Biomedical Engineering
- Johns Hopkins University, B.S.E. in Biomedical Engineering

Speech Topic : Track 6A - New paradigm of academia-industry-government partnership in translational research in drug discovery to development.

Dr. Kao is currently a Vilas Distinguished Achievement Professor of Pharmacy, Surgery, and Biomedical Engineering, University of Wisconsin-Madison, WI, USA.  He holds B.S.E. in Biomedical Engineering from Johns Hopkins University, M.S.E. in Biomedical Engineering, and Ph.D. in Macromolecular Sciences both from Case Western Reserve University.  He held a dual appointment as a postdoctoral research associate in the Institute of Biomedical Engineering at the Swiss Federal Institute of Technology in Zurich, Switzerland and in the Division of Chemistry and Chemical Engineering at the California Institute of Technology.
He has been active in the field of biopharmaceuticals, specifically in the role of biomaterials in the management of diseases. His main research involves mechanisms of cell adhesion and activation on biomaterials, biomaterial biocompatibility and biodegradation, and novel biomaterial for specific biofunctions in manipulating biological responses for therapeutic applications.
He is currently the Associate Dean of the Division of International Studies of the University of Wisconsin (UW), and oversees the UW Shanghai Innovation Office (SIO).  The SIO helps to strengthen UW collaboration with China regarding student academic and internship opportunities, faculty research collaborations, alumni outreach and business partnerships.  He is also currently the Assistant Executive Director of UW NIH-CTSA (University of Wisconsin Institute for Clinical and Translational Research (ICTR). ICTR’s main mission is to create an environment that transforms research into a continuum from investigation through discovery to development, and to connect basic research to clinical research and community outreach to improve outcome. Therefore, his research projects exemplify the necessity of private-public-academia partnerships in the advancement of pharmaceutical sciences and impact on industry.


Songpon Deechongkit, Ph.D.
Managing Director
Siam Bioscience Co.,Ltd.
44 Srijulsup Tower 18th  Floor
Rama I Road, Pathumwan
Bangkok 10330
- The Scripps Research Institute, Ph.D.
- Massachusetts Institute of Technology (MIT), B.Sc.

Speech Topic : Track 6A - "Opportunities and challenges for biosimilars: from global to ASEAN perspective"

Dr. Songpon Deechongkit is Managing Director of Siam Bioscience Co., Ltd.  As a recipient of the King Scholarship, Dr. Songpon received a B.Sc. from Massachusetts Institute of Technology (MIT) and the Ph.D. from The Scripps Research Institute (La Jolla, CA). He then joined Amgen, Inc., in charge of various biopharmaceuticals such as erythropoietins, cytokines, and monoclonal antibodies. He was also on the Amgen Taskforce on Biosimilars.  Since 2000, he has almost 30 publications in journals and books such as Nature, Science, and Advances in Protein Chemistry.  His expertise is in the application of protein sciences to biopharmaceutical and biosimilar development.



Anunchai  Assawamakin, Ph.D.
Research Assistant
Division of Molecular Genetics
Department of Research and Development
Faculty of Medicine Siriraj Hospital
Mahidol University
- Mahidol University, Ph.D. in Immunology
- Mahidol University, B.Sc. in Pharmacy

Speech Topic : Track 6B - QbD for biopharmaceutical development: erythropoietin case.

Dr.Anunchai Assawamakin, obtained his BSc degree in Pharmacy from Mahidol University in 2005. He received the Royal Golden Jubilee scholarship to pursue the Master and Ph.D. degree in Immunology. He had a postdoctoral training at the Biostatistics and Bioinformatics Laboratory, Genome Institute, BIOTEC. His research interests includes QbD, bioinformatics, gene mapping of human diseases, systems pharmacology, human population genomics, and medical informatics.


Bodin Tuesuwan, Ph.D.
Department of Pharmaceutical Chemistry
Faculty of Pharmaceutical Sciences
Chulalongkorn University
Bangkok 10330
- The University of Texas at Austin, Ph.D. in Medicinal Chemistry
- Massachusetts College of Pharmacy and Health Sciences, Graduate Studies in Medicinal Analytical Chemistry
- Chulalongkorn University, B.Sc. in Pharmacy

Speech Topic : Track 6B - Biopharmaceutical quality control: not another twilight zone‌

Dr. Bodin Tuesuwan received his professional degree in Pharmacy with honors in 1998. He attended Graduate Studies in Medicinal Analytical Chemistry at Massachusetts College of Pharmacy and Health Sciences in Boston and Medicinal Chemistry Program at The University of Texas at Austin. Dr. Tuesuwan had returned to Bangkok in 2008 as a faculty member in The Department of Food and Pharmaceutical Chemistry, The Faculty of Pharmaceutical Sciences,Chulalongkorn University. His research interests include: G-quadruplex-cancer relationship, DNA-targeted Drug Design and mechanistic studies. He is currently the Quality Manager of Pharmaceutical Technology Service Center, an ISO/IEC 17025 certified laboratory.


Vorasit Vongsutilers, Ph.D.
Department of Food and Pharmaceutical Chemistry
Faculty of Pharmaceutical Sciences
Chulalongkorn University
Bangkok, 10330

Speech Topic : Track 6B - Biopharmaceutical quality control: not another twilight zone‌

Dr. Vorasit Vongsutilers is a lecturer in the area of Medicinal Chemistry and Drug QA/QC at the Department
of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University. His
Ph.D. and ongoing research involve the synthesis and characterization of the modified nucleic acid used as
a potential biological probe for the detection of disease related proteins. He is currently appointed as the
Director of Pharmaceutical Technology Service Center that is an ISO/IEC 17025 certified laboratory for
drug quality testing. He is also the Head of Medicinal Analytical and Pharmaceutical Chemistry Research
Unit (MAPCU) that is an excellence center focuses on research and service in the field of drug discovery
and development.


Kostas Papadopoulos, Ph.D.
Chief Medical Research and Development
Executive Board Member
THAI StemLife
5/3 Soi Chidlom, Ploenchit Road,
Bangkok 10330
- Lund University, Specialist in Endocrinology-Diabetology
- Lund University, Ph.D. in Endocrinology Immunology
- Lund University, MD in Medicine

Speech Topic : Track 6B - Your Future is in YOU-Gene and Stem cells

Dr. Konstantinos Papadopoulos, MD, PhD is a Greek national fluent in several languages. He has held Specialist, Teaching, and Research Positions at the Department of Endocrinology and Diabetes, University of Lund, Malmoe University Hospital, Malmoe, Sweden. He has worked as a Medical Registrar at the Department of Internal Medicine, Liverpool and Fairfield Hospitals and as Clinical Tutor in Medicine for the overseas doctors training programme in N.S.W., Australia. Furthermore, he has held a Lectureship in Endocrinology at the University of Alexandroupolis, Greece. He has been the Associate Director International Medical Services for Asia/Pacific at Organon International. He has published several papers in the field of endocrine autoimmunity, has performed referee assignments for several Medical Journals and has been an invited speaker and chairman at numerous occasions in the fields of Endocrinology/Diabetology, Infertility and Reproductive Endocrinology, HRT, Anesthesiology, Depression and Stem Cell Biology. His latest peer reviewed publications are on the use of a child’s own cord blood in Cerebral Palsy and own stem cells in osteoarthritis. At present, he is the CMRD of THAI StemLife, an international biotechnology company specializing in umbilical cord blood and peripheral blood adult stem cell storage and R&D as well as Predictive Genetic Testing located in Bangkok, Thailand.


Weerapong  Prasongchean, Ph.D.
Department of Biochemistry and Microbiology
Faculty of Pharmaceutical sciences
Chulalongkorn University
Bangkok, 10330
- University College London, PhD in Stem Cells and Regenerative Medicine
- Imperial College London, MSc in Neuroscience and Cognitive Science
- Chulalongkorn University, BSc in Pharmaceutcal Sciences (R&D)

Speech Topic : Track 6B - Stem cells-based biologicals at a glance

Weerapong Prasongchean obtained a PhD from University College London, UK, where he pursued his PhD on potential of somatic stem cells from different sources for regenerative medicine. Previously, he received a Master of Science in Neuroscience from Imperial College London, UK. He is now a lecturer at Department of Biochemistry and Microbiology, Chulalongkorn University, Thailand. Mr Prasongchean has presented scientific research posters and given talks at many international conferences and public meetings, and published research articles in peer-reviewed journals and book chapters on regeneration and stem cells for personalized medicine. His current research interests include stem cells and regenerative pharmacy.

Vitoon Vonghangool
Managing Director
BioNet-Asia Co., Ltd.
19 Soi Udomsuk 37, Sukhumvit 103 road,
Bangjak, Prakanong, Bangkok 10260
- Boston College School of Management, International Marketing Management
- National University of Singapore, Accounting & Finance Session for Non Financial Manager

Speech Topic : Track 4 - Financing Life Sciences

Mr. Vitoon Vonghangool is the Managing Director of BioNet-Asia Co., Ltd.
With 35 years of experience and expertise in marketing vaccines, Mr. Vitoon is one of the key executives leading BioNet-Asia.  For years, he has been encouraging the vaccine manufacturers within ASEAN for the co-operation on self-sufficiency. He also advocates the local development and production of vaccines against regional diseases, such as dengue, rabies and Japanese encephalitis, present in Thailand and in the region.  
Mr. Vitoon started his career with Rhone–Poulenc Group in 1971 and during his 21 years with the group, he held various positions starting from the bottom as Medical Representative and worked his way up to Marketing Director and then to General Manager .
Since 1992 until present, Mr. Vitoon has been a successful entrepreneur. He founded many enterprises such as Diagnostic Biotechnology Co., Ltd., Biogenetech Co., Ltd., Pharma Nord S.E.A. Co., Ltd., and Biopex Co., Ltd.  focusing on diagnostic products, vaccines, biological and pharmaceutical products, food supplement, and logistics.
Apart from his executive responsibility, Mr. Vitoon has been working as Consultant for Chiron (presently Novartis) in 1998-2001 for human rabies vaccine.
Mr. Vitoon is also a member of the sub-committee (Vaccines Production Project) of the National Vaccine Committee in Thailand.
Mr Vitoon also a member and ones of the founder of The Thai Association for Biotech Industries since 2010

Jerome Kim, M.D.
Deputy Director and Chief
Department of Molecular Virology and Pathogenesi
U.S. Military HIV Research Program
- Yale University School of Medicine
- University of Hawaii, Phi Beta Kappa with highest honors in   

Speech Topic : Track 13 - The Latest HIV Vaccine Development

Jerome H. Kim, M.D., is currently Deputy Director and Chief, Department of Molecular Virology and Pathogenesis at MHRP. He also serves as the HIV Vaccines Project Manager, U.S. Army Medical Materiel Development Activity, Fort Detrick, Md.
Dr. Kim, a Colonel in the United States Army Medical Corps, started his military career in the Air Force, assigned to the Department of Retroviral Research, WRAIR. After a brief exodus, he entered Army service in 2000 in the Department of HIV Vaccine Research, Division of Retrovirology, WRAIR. Prior to serving as Deputy Director (Science), Dr. Kim was the Chief, Department of Retrovirology, U.S. Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand (2004-2008). He has also been the Chief, Biomedical Research Service, Tripler Army Medical Center (2002-2004) and Assistant Chief, Department of HIV Vaccine Development, MHRP (2000-2002).
Dr. Kim’s research interests include HIV molecular epidemiology, host genetics, and HIV vaccine development. He serves as a reviewer for scientific journals and has served on consultations for the World Health Organization and the Global HIV/AIDS Vaccine Enterprise.
Dr. Kim is a Clinical Associate Professor of Medicine at the John A. Burns School of Medicine, University of Hawaii. He is a Fellow of the American College of Physicians and a Fellow of the Infectious Diseases Society of America. Military honors include the Army Commendation Medal and Air Force/Army Meritorious Service Medal with three oak-leaf clusters, and the Order of Military Medical Merit.
Dr. Kim graduated Phi Beta Kappa with highest honors in Biology and high honors in History from the University of Hawaii, Manoa in 1980, where he won the Library Prize for Pacific Islands Area Research and the Arthur Lyman Dean Prize in the Humanities. He graduated from the Yale University School of Medicine in 1984. Dr. Kim completed his training in Internal Medicine (1987) and fellowship in Infectious Diseases (1990) at Duke University Medical Center and was elected into Alpha Omega Alpha while at Duke.



Darnisha Grant Harrison
President & CEO
Ennaid Therapeutics
Located in Atlanta, GA
and Baton Rouge, LA
- Louisiana State University, B.S. in Microbiology and Minor in Chemistry

Speech Topic : Track 14
Ennaid Therapeutics Has The Solution, The Team and The Plan To Safely and Rapidly
Develop And Commercialize A Cure For All Four Strains Of Dengue Virus

Darnisha Grant Harrison, President & CEO: Darnisha is responsible for guiding the strategic direction and growth of Ennaid. Once a Microbiologist, Darnisha is now a biopharmaceutical entrepreneur with greater than nineteen years of experience in the Life Sciences. Prior to founding Ennaid, she spent three years as a scientist, most notably at Amgen and at the University of Georgia. She also spent sixteen years in Business Development/Licensing as a Director in various companies in the biopharmaceutical industry, most notably Penwest/JRS Pharma, Metrics, Inc, Banner Pharmacaps and Norwich. She is an expert negotiator and deal-maker in identifying, negotiating/closing drug development deals and strategic collaborations. Darnisha is expertly skilled in strategic business planning and brisk, successful execution of such plans. She received a B.S. in Microbiology and Minor in Chemistry, from Louisiana State University (LSU).



Walter H. Gunzburg
Chairman of the Board and Chief Technical Officer Austrianova Singapore/Austrianova Thailand
- Imperial Cancer Research Fund, London, UK, Ph.D., University of Munich, Senior Lecture (Privatdozent) University of Veterinary Medicine, Vienna, Full Professor of Virology

Speech Topic : Track 14

Prof. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova Singapore/Austrianova Thailand. He has had many years of experience in the biotech industry and was chief scientific advisor to the vaccine company, Bavarian Nordic. Currently, he is founder and board member of ViruSure, a virus and prion testing company located in Vienna. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, and the U.S. biotech company, Tocagen Inc, all of which developed/are developing advanced medicinal treatments for cancer.
Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years whilst he was a member of the German Medical Association’s Central Commission for Somatic Gene Therapy. He continues to be an active researcher and has published more than 130 peer-reviewed scientific publications, many in high impact international journals, as well as numerous book chapters. Notably, he co-authored the first German language textbook on gene therapy. As well as being a member of the editorial board of a number of international gene and cell therapy journals such as Trends in Molecular Medicine, he is an active reviewer for many top tier journals such as Nature Medicine, Trends in Genetics. He is also a reviewer of international competitive grants and a regular speaker at International Scientific meetings.


Organizers Organizers
© 2013 Thailand Center of Excellence for Life Sciences (TCELS)

22 FL. CMMU Building 69 Vibhavadi Rangsit Rd., Samsennai, Phayathai, Bangkok, 10400 Thailand Tel: +6626445499
Powered by SaaS Labs Team SaaS Labs Team